ESR1 and neoplasm: Dual blockade of ER and HER2 with neratinib plus fulvestrant was associated with significant inhibition of tumor growth and prolonged survival in HR+/HER2+ breast tumor xenografts unresponsive to ET compared with single-agent neratinib or controls52.